Boston Scientific invests $1.5 billion in MiRus for TAVR expansion
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
The patient, suffering from calcific severe aortic stenosis—a dangerous narrowing of the heart valve caused by calcium buildup—had run out of standard treatment options
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The Evolut FX TAVR system is used for treatment of symptomatic severe aortic stenosis and it has features that enhance ease-of-use and predictable valve deployment
Subscribe To Our Newsletter & Stay Updated